[Form 4] RESMED INC Insider Trading Activity

Rhea-AI Filing Summary

Michael J. Farrell, Chief Executive Officer of ResMed (RMD), reported option exercises and stock sales executed under a Rule 10b5-1 plan adopted 10/31/2024. On 10/07/2025 he exercised 8,009 options at an exercise price of $101.64 and immediately sold 8,009 shares in multiple trades at weighted average proceeds of $282.8483 per share (runs reported between $280.95 and $283.90). Following these transactions, his beneficial ownership decreased from 475,801 shares to 467,792, with 2,090 shares held indirectly by the Lisette and Michael Farrell Family Trust. The options exercised vest on a schedule that began 11/11/2019 and expire 11/14/2025.

Positive

• Transactions executed under a Rule 10b5-1 plan, showing preplanned trading and compliance
• Exercise price paid of $101.64 on 8,009 options (captures long‑term compensation realization)

Negative

• Direct beneficial ownership decreased by 8,009 shares from 475,801 to 467,792
• Options expire soon on 11/14/2025, which may prompt further exercises or sales in near term

Insights

Corporate Governance Analyst

Insider used an established Rule 10b5-1 plan to exercise options and sell shares.

The transactions show an officer exercising 8,009 options at $101.64 and selling the same number of shares at a weighted average of $282.85, consistent with a pre‑arranged trading plan adopted 10/31/2024. This pattern reduces direct beneficial ownership from 475,801 to 467,792.

The primary dependence is the 10b5-1 plan timing and option vesting/expiration (options expire 11/14/2025). Watch for any further scheduled exercises or plan disclosures near option expiration over the next few months.

Compensation & Equity Specialist

Option exercise and immediate sale are execution of equity compensation, not an intra-day trading signal.

The exercised options had an exercise price of $101.64 and zero reported cash price for derivative conversion, implying standard option settlement and immediate disposition of the resulting shares. Vesting began 11/11/2019 with a three-year tranche schedule (1/3 per year).

Given the option expiration on 11/14/2025, monitor equity plan activity and future Form 4s for additional exercises as expiration approaches.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farrell Michael J.

(Last) (First) (Middle)

RESMED INC.

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	10/07/2025		M(1)		8,009	A	$101.64	475,801	D
ResMed Common Stock	10/07/2025		S(1)		8,009	D	$282.8483(2)	467,792	D
ResMed Common Stock								2,090	I	Lisette and Michael Farrell Family Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
ResMed Common Stock Options	$101.64	10/07/2025		M			8,009	11/11/2019(3)	11/14/2025	ResMed Common Stock	8,009	$0	8,011	D

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.

2. This transaction was executed in multiple trades at prices ranging from $280.95 - $283.90. The price reported above reflects the weighted average sale price.

3. Represents date options first become exercisable. Options vest 1/3 per year.

	Michael J. Farrell, Chief Executive Officer	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did RMD CEO Michael J. Farrell report on his Form 4?

He reported exercising 8,009 options at $101.64 and selling 8,009 shares on 10/07/2025, using a Rule 10b5-1 plan adopted on 10/31/2024.

How did Michael Farrell’s ownership change after the transactions?

Direct beneficial ownership fell from 475,801 shares to 467,792 shares; an additional 2,090 shares are held indirectly via the Lisette and Michael Farrell Family Trust.

At what prices were the shares sold?

Sales executed between $280.95 and $283.90, with a weighted average sale price of $282.8483 per share.

When do the exercised options expire and when did they first become exercisable?

The options first became exercisable on 11/11/2019 and expire on 11/14/2025; vesting occurred at one‑third per year.

Was the sale part of a preplanned trading arrangement?

Yes; the Form 4 indicates the transactions were made under a Rule 10b5-1 trading plan adopted on 10/31/2024.